SUBSCRIBE
SUBSCRIBE
Tristan Manalac

Tristan Manalac

Contributing Writer | News

Tristan is an independent science writer based in Metro Manila, with more than eight years of experience writing about medicine, biotech and science. Being formally trained in molecular biology, he once dreamed of collecting degrees and starting his own lab. But these days, he finds his greatest joy in a bottle of beer and a beautiful sentence. He can be reached at tristan.manalac@biospace.com, tristan@tristanmanalac.com or on LinkedIn.

Pictured: FDA signage at its office in Washington, DC
FDA
Neurocrine Wins FDA Approval for ‘Sprinkle’ Formulation of Ingrezza for Huntington’s Disease Chorea
Neurocrine Biosciences on Tuesday won the FDA’s approval for a sprinkle capsule formulation of Ingrezza, providing a more convenient route of treatment for Huntington’s disease patients with trouble swallowing.
May 1, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Eli Lilly's headquarters in Indianapolis
Business
Lilly Touts 26% Q1 Revenue Growth on Strong Mounjaro Sales, Raises Full-Year Guidance by $2B
Thanks to strong sales of its blockbuster drugs Mounjaro and Zepbound, Eli Lilly on Tuesday reported nearly $8.77 billion in revenue in the first quarter of 2024, while raising its full-year revenue guidance by $2 billion.
April 30, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Pfizer's signage at its world headquarters in New York
FDA
Pfizer, Genmab’s ADC Tivdak Scores Full FDA Approval in Recurrent or Metastatic Cervical Cancer
Based on strong overall and progression-free survival data in its Phase III confirmatory study, Pfizer and Genmab’s antibody-drug conjugate Tivdak on Monday secured the FDA’s full approval for recurrent or metastatic cervical cancer that had progressed on or after chemotherapy.
April 30, 2024
 · 
2 min read
 · 
Tristan Manalac
AstraZeneca's sign on its office in California
Drug Development
AstraZeneca, Daiichi Sankyo Continue Earlier-Line Breast Cancer Push with Phase III Enhertu Win
AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate Enhertu significantly improved progression-free survival in metastatic breast patients with low and ultralow HER2 expression levels who had received at least one line of systemic treatment.
April 30, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Johnson & Johnson Business Center in Switzerland
Business
J&J-Partnered Addex Fails Phase II Epilepsy Study, Mulls Future of Candidate
Johnson & Johnson and Addex Therapeutics’ epilepsy hopeful ADX71149 did not meet its primary endpoint of time to reach baseline seizure count in a mid-stage trial, as the partners look to determine the next steps for the program.
April 29, 2024
 · 
2 min read
 · 
Tristan Manalac
3D illustration of blood cells being produced in the bone marrow
Drug Development
Safety Concerns with MorphoSys’ Blood Cancer Drug Could Mar $2.9B Novartis Buy: STAT
Citing anonymous sources involved in a Phase III trial, STAT News reported Sunday that MorphoSys’ pelabresib may worsen the risk of progression to acute myeloid leukemia, potentially putting Novartis’ proposed $2.9 billion acquisition at risk.
April 29, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Deloitte's building in Canada/iStock, Re
Drug Development
Pharma R&D ROI Spikes in 2023 as ‘Breakthroughs’ Re-Energize Industry: Report
After a record low in 2022, the pharma industry in 2023 saw a surprise rebound in productivity following one of its slowest years on record, according to a report from audit firm Deloitte.
April 29, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Syringe drawing vaccine from a vial
Drug Development
Bavarian Nordic’s Mpox Vaccine Safe, Effective at Lower Doses: Study
A one-fifth dose of Bavarian Nordic’s mpox vaccine Jynneos can elicit a similar antibody response as its standard-dose regimen, according to findings presented Saturday at the European Society of Clinical Microbiology and Infectious Diseases Global Congress.
April 29, 2024
 · 
2 min read
 · 
Tristan Manalac
Gilead's corporate headquarters in Silicon Valley
Business
Gilead Touts 5% Revenue Jump, Positions for 2024 Growth and Culls Pipeline
Gilead on Thursday reported revenue growth in the first quarter of 2024, driven by the strong sales of its HIV, cancer and liver diseases franchises, while culling a number of candidates.
April 26, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Cigna Group signage outside its office i
Drug Delivery
Cigna’s Evernorth to Offer Humira Biosimilar with No Out-of-Pocket Cost
Starting in June 2024, Evernorth Health Services will offer Humira biosimilar products with no out-of-pocket cost through its Accredo specialty pharmacy.
April 26, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Sign above the entrance to a U.S. courthouse
Policy
GSK Sues Pfizer and BioNTech Over Alleged COVID-19 Patent Infringement
With its lawsuit filed against Pfizer and BioNTech, the British multinational biopharma has joined the high-profile patent battle over mRNA technology used in COVID-19 vaccines.
April 26, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Entrance to Pfizer's office in Belgium
FDA
Pfizer Secures FDA Approval for Hemophilia B Gene Therapy, Launches Warranty
Pfizer will go toe-to-toe with CSL Behring following the FDA’s Friday approval of its hemophilia B gene therapy Beqvez and will launch a warranty program based on the durability of response.
April 26, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Bristol Myers Squibb office in California
Business
BMS to Cut 2,200 Jobs in $1.5B Restructuring as Opdivo Sales Drop in Q1
Bristol Myers Squibb announced Thursday it is implementing major cost-cutting measures including thinning out its management layers. The pharma also reported modest revenue growth despite taking a 6% sales hit for lung cancer therapy Opdivo.
April 25, 2024
 · 
2 min read
 · 
Tristan Manalac
Facade of Novo Nordisk's office in Fremont, California
Policy
Sanders Launches Probe of ‘Outrageously High Prices’ of Novo’s Ozempic, Wegovy
Sen. Bernie Sanders (I-Vt.) on Wednesday launched an investigation into the exorbitant prices of Novo Nordisk’s Ozempic and Wegovy blockbusters, and has asked the Danish drugmaker to justify their price tags.
April 25, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: FDA signage at its office in Washington, DC
FDA
FDA Approves UTILITY’s New Antibiotic for Uncomplicated UTI in Women
The regulator on Wednesday gave its approval for a new oral antibiotic to treat uncomplicated urinary tract infections in women. UTILITY therapeutics expects to launch Pivya in the U.S. in 2025.
April 25, 2024
 · 
2 min read
 · 
Tristan Manalac
Load More